España transforma

Executive Summary

PERTE: For Cutting-edge Health.

GOBIERNO DE ESPAÑA

Plan de Recuperación Transformación y Resiliencia

#EspañaTransforma

1 Cutting-edge health – a priority for the Government of Spain

The Spanish health system is an internationally recognised model characterised by the equality and quality in the provision of services. However, the pandemic and its consequences on people and on the economies of the most developed countries have demonstrated that **the next stage of the health protection and promotion mustbe based on a qualitative transformation of the health sector closely tied to science and innovation.**

A high performance health system must not only be oriented to disease care, but particularly to **health protection and its interaction with new environmental, demographic and socio-economic challenges.** The **priorities of health promotion and healthcare** must remain focused on prevention, diagnosis, treatment and the rehabilitation of the most common pathologies, many of which are **chronic diseases associated with the ageing population.** At the same time, it is also essential to focus on the millions of people with **low prevalence and extremely rare diseases** whose diagnosis and therapeutic possibilities require the most daringly innovative programmes.

The concept of **Cutting-edge health,** which is coined in this strategic project, refers to the **process of promotion and protection of health based on the development and incorporation of innovative products and procedures and digital solutions** that offer added value to the prevention, diagnosis, personalised treatment and rehabilitation of patients and allow new health challenges to be addressed.

Among the innovative clinical approaches founded on science and innovation is the so-called **Precision Medicine**, which is understood as a clinical process that **incorporates genomic data from people and combines them with clinical and radiological data, environmental exposure, living habits and socio-economic determinants** along with other relevant health data with the aim of obtaining more precise and integrated information to take decisions on individual and public health. This process implies the need to develop new

biomarkers, diagnostic and predictive tools and technological solutions based on **Data Science**.

Furthermore, and closely related to Precision Medicine, **developments have been made in the field of genetics, molecular biology and tissue engineering** that have led to an unprecedented therapeutic revolution based on new capacities to figure out and modify the information recorded on our genome, our cells and our tissue. The so-called **advanced therapy medicines** include genome therapy, cell therapy and tissue engineering, and are the paradigm of **therapeutic innovation geared to the needs of each patient**, specifically designed for each person that suffers from a disease.

The innovative clinical approaches of Precision Medicine and new advanced therapy medicines offer a **great opportunity to improve the health of the population**, while opening up a huge field to generate **economic value linked to the science, innovation and digitalisation**.

What is cutting-edge health?

It is the promotion and protection of health based on the development and incorporation of innovative products and procedures and digital solutions that offer added value to the prevention, diagnosis, personalised treatment and rehabilitation of patients.



Precision Medicine | **Advanced therapy medicines** | **Data Science and Artificial Intelligence**

2 The need for a PERTE in the health sector

The Strategic Project for Economic Transformation and Recovery (known as PERTE) for Cutting-edge Healthcare is conceived as a country proposal of general interest for the economy as a whole, due to its knock-on effect and transformative potential, and also for society, boosting quality jobs and improving the health of the Spanish citizens. Scientific knowledge, cutting-edge healthcare innovation and data are identified as vectors of transformation. The Strategic Project will act as a principal backbone and as a "tractor" project to consolidate collective and individual health protection from any threat, regardless of its scale. In addition to that, it is considered as one of the key elements of the socio-economic recovery.

The health sector in Spain presents itself as one of the main dynamos of the economy, with a clear potential for development and innovation. **In 2019, the public health spending in Spain amounted to 75.03 billion euros, which represents 6% of the Gross Domestic Product (GDP).** The annual average growth in public health spending in the five-year period 2015-2019 was 3.4%. On the other hand, considering the entire health sector, a recent report estimates that **economic activities related to health** generated a gross added value of around 94.6 billion euros, equivalent to 8.7% of GDP.

In a context in which the structure of the pharmaceutical market and conventional models of development and commercialisation of innovative products raise globally concerns about the sustainability of a health system that guarantees access to cutting-edge health for the whole population, **an entrepreneurial State invests in new models to develop medicines and health products through the public academic sector, explores innovative manufacturing mechanisms and fosters public-private collaboration.**
The PERTE for Cutting-edge Health will create a **virtuous circle** among the stakeholders with the aim of rolling out the technological and industrial capacities needed to allow the generation of a high performance health system aimed at health protection, providing an immediate and flexible response to health challenges and fostering sustainability. This health system

will be based on **Precision Medicine, advanced therapies and artificial intelligence**. To ensure this transformation, it will be necessary to foster the transfer of academic R&D+i to the industrial sector through public-private collaboration tools and the promotion of industrial capacities through innovation in industrial and manufacturing processes.

The health sector in Spain is one of the main dyanmos of our economy, with a clear potential for development and innovation, and job creation.

€75.03 billion spent on public health in 2019

accounting for

of GDP

3 Cutting-edge Health in the Recovery, Transformation and Resilience Plan

The Recovery, Transformation and Resilience Plan sets out the roadmap for the modernisation of the Spanish economy, the recovery of economic growth and job creation. In this context, the Recovery Plan strengthens public and private investment to readdress the productive model, while boosting the green and digital transitions through 10 lever policies and 30 components.

Lever policy VI refers to "Promotion of science and innovation and strengthening of the capabilities of the National Health System". This lever policy includes among its components the so-called Institutional reform and capacity-building in the national science, technology and innovation system (Component 17) which encompasses, among others, a set of actions that are aimed at harnessing the development and innovation potential in the health sector.

Accordingly, Investment 6 (I6), which is structured around health, foresees the design and implementation of an emblematic project of Precision Personalized Health. Other reforms and investments of Component 17 are also linked to the aims of this PERTE, such as the implementation of a Supplementary Plan in the Biotechnology Sector (Investment 1 – I1) and the reform of the Science Law, which will improve scientific careers, along with the transfer of knowledge between the NHS and the industrial sector.

Given the strategic nature of the health sector, the actions included in this PERTE go beyond the field of R&D+i and extend to industry and digital transformation. For this reason, the components of the Recovery Plan related to the PERTE are multiple. All of them contribute to the qualitative transformation of the health sector proposed by the PERTE (see details in Annex I).

Components of the Recovery Plan related to the Cutting-edge Health PERTE



4 Cutting-edge Health PERTE and the Recovery Plan

The **general aim of the PERTE** is fostering the sustainable generation of a renovated, resilient and prosperous industrial sector, which leads to the creation of transgenerational and quality jobs through bidirectional and cohesive public-private collaboration. The PERTE focuses on the protection of collective and individual health through a digitally transformed high performance health system.

The PERTE **is structured through a matrix design with four strategic goals and five lines of action to be applied in a cross-cutting fashion way** to guarantee the achievement of the goals. So, the lines of action are identified as critical elements of success.



1.1. Strategic Goals

SG1. Boost the fair implementation of Personalised Precision Medicine in the National Health System as a tool to tackle new health challenges and their interaction with environmental, demographic and socio-economic challenges, while fostering the strengthening, development and creation of competitive companies based on the generation of knowledge.

SG2. Promote the development of advanced therapies and other innovative and emerging medicines and facilitate their transfer to clinical practice through the necessary alliances between academic and business sectors, and strengthen the industrial sector due to the intensive use of knowledge.

SG3. Develop a system of innovative data that involves the collection, processing, analysis and exploitation of data from different sources to improve prevention, diagnosis, treatment, rehabilitation and health-oriented research.

SG4. B Boost the digital transformation of healthcare, through the application of technology to all activities that imply relations with citizens and also to the management resources in all health care areas, with a particular emphasis on strengthening primary care and equality in access to quality healthcare, under conditions of cybersecurity.

1.2. Cross-cutting lines

CL1. Strengthen and develop capacities of National Health System centres to maintain Spain's leading position in clinical research and retain the investments made by multinational pharmaceutical companies, bolstering the figure of the health professional researcher.

CL2. Invest in the development, digitalisation and modernisation of industrial capacity and facilitate value chains developments towards diagnostic, therapeutic and rehabilitation innovation with a high added value for both people and public authorities, expanding our industrial autonomy.

CL3. Design and deploy instruments and structures that ensure collaboration and coordination between the scientific and business sector throughout the value chain of innovative products**.**

CL4. Strengthen territorial cohesion by incorporating all the Autonomous Communities in a transformation process aimed at the whole health system, and which also seeks to foster health innovation and opportunities for technical and industrial development throughout the whole country.

CL5. Strengthen training based on alliances between companies, NHS centres and research institutions.



Schematic representation of strategic goals and cross-cutting lines

The strategic goals and cross-cutting lines have a **significant interconnection** and great mutual dependence, and the combined and simultaneous development of each of them is essential. This is due to the fact that the generation of a high-performance healthcare system based on Personalised Precision Medicine demands industrial development and enhanced industrial and business skills which, in turn, requires powerful health R&D+i oriented to people's problems and with real transfer capacity to the productive sector. All this, in turn, requires new vocational training models and the training of qualified professionals who will end up being the talent on which the virtuous circle of this Cutting-edge Health PERTE is based.

5 Budget and Investments tools

The Cutting-edge Health PERTE provides for an **investment of more than 1.47 billion euros** in the period 2021-2023, with **a public sector contribution of 982.44 million euros and an initial private investment of 486.88 million euros.**



This strategic project **encompasses and coordinates two investment agendas**: one aimed at the scientific academic sector, and the other at the business industrial sector, particularly promoting scientific-business alliances. These investment agendas are structured through the following tools:

1) **National call for proposals** aimed at the scientific sector, the industrial sector and collaboration projects that combine the two investment agendas.

2) **Creation of an R&D+i structure for advanced network therapies** that allows the existing designs to be structured throughout the whole country.

3) **Creation of a public-private investment vehicle** in advanced therapies (public-private trading company), with the participation of companies with production capacity in Spain.

4) **Elements of coordination and early identification of the capacities required** in the National Health System.

5) **Innovative and pre-commercial public procurement**.

6) **Agreements with Autonomous Communities and agreements** at Sector Conferences.

7) **Private initiatives and projects co-programmed** through the Cutting-edge Health Alliance with the leadership of the industrial sector.

8) **Public tenders.**

Annex II sets out a summary of the actions and investments associated with the PERTE.

6 Impact and Results

It is estimated that the Cutting-edge Health PERTE will generate a global contribution to GDP of up to 4.34 billion euros and the creation of up to 12,688 new jobs.

From the perspective of health impact, a **minimum saving of 15% in disability-adjusted life years** (DALYs) for each of the pathologies associated with the actions under this PERTE is estimated, and **a reduction of 30% in inter-territorial differences in healthy life years** over the age of 65 is foreseen.

The following achievements are expected:

- **Biomedical innovation in the National Health System will consolidate as a driving force of the change of productive model**, boosting quality jobs, economic development and strengthening the industrial sector.

- **The Spanish National Health System will become a global benchmark in Precision Medicine** through the massive and smart use of different data sources (biological, environmental, functional, behavioural and others) for health benefits.

- **Public-private collaboration will become a tool used daily** in the development of R&D+i from the National Health System, **reflected in the development of advanced therapy medicines and other emerging therapies.**

- **The application of digital technologies** will help offer people **personalised healthcare, adapted to their living and health circumstances,** with equal access, prevention and remote detection capacities and continuous healthcare, while providing professionals with transparent access to data, to collaboration with other health services and to systems to support decision-making.

- The development of new industrial capacities and the modernisation and digitalisation of existing ones will ensure a **competitive industrial sector, with the necessary autonomy to quickly offer solutions needed by society.**

- **Primary and community care under the digitally transformed National Health System** will be integral, accessible, high quality and fair.



Figure. Main achievements under the Cutting-edge Health PERTE within 5 years

€4.34 billion. Contribution to GDP	**12,688 Jobs created**	**Health impacts**
2,176 Innovative actions and transformation of NHS	**9,141** Innovative actions and transformation of NHS	
1,159 Digitalisation	***1,527*** Digitalisation	Minimum saving of **15%** of **disability-adjusted life years**
1,000 Strengthening Industrial Development	***2,020*** Strengthening Industrial Development	**Reduce %** Inter-territorial differences in healthy life years over the age of 65 **by 30**

7 Governance

The interrelation between the different public and private stakeholders and between the different departments of the Central Government that participate in the PERTE requires a specific structure of governance that makes the collaboration model effective for the qualitative transformation sought.

As regards coordination between the different departments, a system of inter-ministerial governance is established which, by setting up a working group chaired by the Minister for Science and Innovation and the Minister for Health and made up of representatives from all the departments that participate in the PERTE will serve as a framework for its stable collaboration and coordination.

In addition, governance is required to integrate public-private collaboration and guarantee ongoing dialogue. To that end, the Cutting-edge Health Alliance is created. This alliance includes all the parties involved: public authorities, biomedical research centres and departments, hospitals and health centres, along with companies – from the smallest emerging companies to the largest ones. By doing this, high levels of coordination will be achieved in a space of biomedical research that guarantees the critical elements of success of the PERTE by adopting highly innovative solutions. The Alliance will also be open to the participation of representatives of both citizens and patients. The Vice--ChairPerson of the Alliance will be a person of recognised prestige in the health sector.


Public authorities
Ministerial departments and Autonomous Communities
Healthcare centres
Hospitals and primary care centres
Companies
(Biotechnology and pharmaceutical sector)
Research centres and departments
(Public research organisations, IIS, foundations, universities)
Online cooperative research structures
Cutting-edge Health
Alliance

8 Timeline

TIMELINE FOR CUTTING-EDGE HEALTH PERTE	BODY	START DATE	END DATE
Actions associated with SG1: Personalised Precision Medicine			
Financing for the generation and transfer of knowledge in the form of R&D+i projects to cater for the needs of research bodies and biotechnology companies			
Carlos III Health Institute (ISCIII) call for Proposals for Personalised Precision Medicine	ISCIII, Ministry of Science and Innovation	Q3 2021 Q3 2022	Q4 2021 Q4 2022
Incorporation of innovative techniques and technologies in the NHS			
Support for and collaboration with biotechnology companies in the development and clinical application of new biomarkers, diagnostic technology and predictive medicines to identify individual risks. Innovative public and pre-commercial procurement.	CDTI, Ministry of Science and Innovation	Q2 2022	Q4 2023
Action associated with SG2: Development of advanced therapies and other innovative medicines			
Financing of clinical research projects geared to the development of medicines at an academic level (independent clinical research)			
ISCIII call for proposals for Independent Clinical Research and Advanced Therapies (Clinical trials by researchers)	ISCIII, Ministry of Science and Innovation	Q1 2021	Q4 2021
Public-private collaboration projects through specific rounds of proposals in advanced therapies and emerging medicines			
New Science and Innovation Mission aimed at Advanced Therapies and Emerging Medicines	CDTI, Ministry of Science and Innovation	Q3 2021	Q4 2021

ISCIII-CDTI Joint call for Proposals in Innovation associated with Personalised Medicine and Advanced Therapies	CDTI-ISCIII, Ministry of Science and Innovation	Q2 2022	Q4 2022
Online R&D+i innovation hub in advanced therapies			
Advanced Therapies Consortium (C-TA)	ISCIII, Ministry of Science and Innovation	Q2 2022	Start of Q4 2023
Platforms to support R&D and transfer			
ISCIII platforms to support research (biobanks-biomodels, ITEMAS, SCREN)	ISCIII, Ministry of Science and Innovation	Q1 2021	Q4 2023
Public-private co-investment and collaboration instrument			
Advanced therapy medicines trading company (S-TA)	CDTI, Ministry of Science and Innovation	Q2 2022	Q4 2022
Actions associated with SG3: Innovative data system for NHS and SG4: Digital transformation of primary care			
Digital Health Strategy of NHS			
Health data lake	SEDIA, Ministry of Economic Affairs and Digital Transformation	Q4 2021	Q4 2025
Digital transformation of healthcare in primary and community care	Ministry of Health	Q2 2022	Q2 2026
Actions in field of AI			
Missions programme in AI, health sector	SEDIA, Ministry of Economic Affairs and Digital Transformation	Q3 2021	Q4 2023
Integration of AI in value chain, health sector	SEDIA, Ministry of Economic Affairs and Digital Transformation	Q3 2021	Q4 2025
Multidisciplinary centre to apply AI to development of technologies for health	SEDIA, Ministry of Economic Affairs and Digital Transformation	Q3 2021	Q4 2025

Actions related to CL1: Strengthen and develop the capacities of National Health System centres			
ISCIII-autonomous region agreements to strengthen NHS clinical research capacities (infrastructures, digitalisation, clinical trial units)	ISCIII, Ministry of Science and Innovation	Q2 2022	Q3 2023
ISCIII clinical research platform (SCREN)	ISCIII, Ministry of Science and Innovation	Q1 2021	Q4 2023
Actions related to CL2: Develop and modernise industrial capacity geared towards innovation			
MINCOTUR Call for Proposals: Support for industrial innovation and sustainability projects in processes and products in the pharmaceutical sector and for health products	Ministry of Industry, Commerce and Tourism	1. April/Q2 2022 2. April/Q2 2023	Resolution in October/Q4 2022 Resolution in October/Q4 2023
Direct co-investments in the field of biohealth to strengthen its technological and industrial capacities, through the company Innvierte	CDTI, Ministry of Science and Innovation	Q1 2021	Q4 2022
Fund to support productive industrial investment	Ministry of Industry, Commerce and Tourism	Q3 2021	Virtual office open throughout 2022 and 2023
Line of aid for R&D+i projects in the field of connected industry-active financing	Ministry of Industry, Commerce and Tourism	1. April/Q2 2022 2. April/Q2 2023	Resolution in October/Q4 2022 Resolution in October/Q4
Line of support for innovation and sustainability plans in the field of manufacturing industry	Ministry of Industry, Commerce and Tourism	1. April/Q2 2022 2. April/Q2 2023	Resolution in October/Q4 2022 Resolution in October/Q4 2023
Actions related to CL3: Collaboration and coordination between scientific and industrial fabric			
Portfolio of innovation projects in health	ISCIII, Ministry of Science and Innovation	Q1 2021	Q4 2023
System to monitor projects in pre-clinical phases	ISCIII, Ministry of Science and Innovation	Q1 2021	Q4 2023
Technology transfer funds specialised in field of biohealth, set up through company Innvierte	CDTI, Ministry of Science and Innovation	Q2 2021	Q4 2021

Actions related to CL4: Territorial cohesion			
Supplementary R&D+i plans in biotechnology applied to health (co-investment with Autonomous Communities)	Ministry of Science and Innovation	Q4 2021	Q3 2024
Actions related to CL5: Training			
Support for training in management of health research (Carlos III Health Institute)	ISCIII, Ministry of Science and	Q2 2021 Q2 2022	Q4 2021 Q4 2022
Research, Innovation and Training Centre in Experimental Surgery	-	Q2 2022	Q4 2023
Acquisition of digital skills	Ministry of Health	Q1 2022	Q4 2023
Support programme to attract talent	SEDIA, Ministry of Economic Affairs and Digital Transformation	Q1 2022	Q4 2023

ANNEX I. Components of RTRP associated with PERTE

Table 1 Components of Recovery Plan associated with Cutting-edge Health PERTE

Component of Recovery Plan	Reform or Investment under Recovery Plan	Measure
Component 17 – Institutional reform and capacity-building in the national science, technology and innovation system	Investment 6 - Health	Health. A flagship project in personalised precision medicine with the aim of improving the health of the Spanish people, employing scientific knowledge and innovation.
	Investment 1 – Supplementary Research and Development plans with Autonomous Communities	Supplementary plans in the field of biotechnology and health
	Investment 3 – New private, interdisciplinary, public R&D&I projects, concept tests and the award of aid as a result of international competitive calls. Cutting-edge R&D geared to societal challenges. Pre-commercial public procurement	Pre-commercial public procurement.
	Investment 5 – Knowledge transfer	Venture capital, co-investment and investment in companies with strategic technology measures
	Reform 1 – Reform of the Science, Technology and Innovation Law	Reform of Science Law
Component 12 – Industrial Policy Spain 2030	Investment 2 – Programme to boost competitiveness and industrial sustainability	Programme to boost competitiveness and industrial sustainability. This investment fundamentally seeks to boost the transformation of strategic value chains in industrial sectors with a major knock-on effect on the economy, encompassing all stakeholders that participate in this value chain, from the smallest emerging companies to largest one, from the academic world to research staff and from service providers to suppliers. Given the structure of industrial companies in Spain, an important component to support SMEs was provided for. Health is among the project to be funded.

Component 16 – National Strategy for Artificial Intelligence	R1.1 To boost scientific research, technological development and innovation in AI. R1.4 To integrate AI in value chains to transform the economic fabric	Rounds of support and other actions to finance large projects that use AI, fostering collaboration between research bodies, large companies and SMEs in strategic sectors, including the health sector. Programme to support companies to integrate AI and robotics in their value chains.
Component 18 – Renewal and expansion of the capabilities of the National Health System.	Investment 6 – Health data lake	Health data Lake. Generation of a repository of health data which gathers information from different information systems with the aim of facilitating mass data analysis to support and improve diagnostics and treatment. This measure are part of a broader process to boost the digitalisation of health services, interoperability, cybersecurity and online services at a national, European and international level.
	Reform 3 – Strengthening cohesion, equity and universality	Personalised precision health. The flagship project of personalised precision health, described in Investment 6 of Component 17 requires planning, organisation and implementation in the NHS, to which end different lines of action are provided for in Component 18. Noteworthy among these are the contents of Reform 3: increase in the common portfolio of public health services to be provided to the public in general, specifically genome medical services and the Plan to redirect highly complex care in the health system, which seeks to establish specific requirements in a coordinated fashion to provide more effective care for highly complex pathologies.
Component 11 – Modernisation of public administration	Investment 3 - Digital Transformation and Modernisation of the Ministry of Territorial Policy and the Civil Service and of the administration of the Autonomous Communities and the local authorities	Contribute to strengthening primary and community care under the National Health System and foster its recovery with the aim of it being integral, accessible, high quality, with lasting resolution capacity, and which fosters equality to care for people's health and address the challenges stemming from the health and social crisis caused by the COVID-19 pandemic.
Component 19 - National Plan for Digital skills	Investment 3- Digital skills for employment Investment 4- Digital Professionals	Training programmes in digital skills of the employed, and of the unemployed to improve their employability and programmes to attract and retain talent in this field.
Component 20 – Strategic Plan for Vocational Training	Vocational Training Plan	Reforms and investments to promote training and re-training, with a specific emphasis on such priority sectors as the health sector

ANNEX II: Summary of actions and investments

Scope of action	Action	Measure	Public contribution in 2021	Public contribution in 2022	Public contribution in 2023	Public contribution (million euros)	Private Investment (million euros)
Actions associated with Specific Goal 1: personalised medicine	Financing for the generation and transfer of knowledge in the form of R&D+i projects to cater for the needs of research bodies and biotechnology companies	ISCIII Call for Proposals for Personalised Precision Medicine	29.5	81.5	-	111	-
	Incorporation of innovative techniques and technologies in the NHS	Support for and collaboration with biotechnology companies for the development and clinical application of new biomarkers, diagnostic technology and predictive medicines to identify individual risk. Innovative and pre-commercial public procurement	-	36.6	-	36.6	-

Scope of action	Action	Measure	Public contribution in 2021	Public contribution in 2022	Public contribution in 2023	Public contribution (million euros)	Private Investment (million euros)
	Financing of clinical research projects geared towards the development of medicines at an academic level (independent clinical research)	ISCIII Call for proposal for Independent Clinical Research and Advanced Therapies (Clinical trials performed by researchers)	15	-	-	15	-

Actions associated with Specific Goal 2: development of advanced therapies and innovative medicines	Public-private collaboration projects through specific rounds of proposals in advanced therapies and emerging medicines	CDTI Call for Proposals: Mission in Advanced Therapies and Emerging Medicines (RNA)	31.25	-	-	31.25	25
		Joint ISCIII-CDTI Call for Proposals in innovation associated with Personalised Medicines and Advanced Therapies	-	20		20	10
	Creation of an R&D+i structure for advanced therapies with an online system that allows existing capacities throughout the country to be structured	Creation and development of Advanced Therapies Consortium	7.5	15	-	22.5	-
	Platforms to support R&D and the transfer of knowledge	ISCIII platforms to support research (biobanks, biomodels - ITEMAS, SCREN)	9	9	-	18	-
	Public-private co-Investment and collaboration instrument	Advanced therapy medicines trading company (S-TA)		36.685		36.685	38.182

Scope of action	Action	Measure	Public contribution in 2021	Public contribution in 2022	Public contribution in 2023	Public contribution (million euros)	Private Investment (million euros)
Actions associated with Specific Goals 3 and 4 – Digitalisation and Digital Health	Digital Health Strategy of NHS	Agreements with Autonomous Communities within the framework of the Digital Health Strategy of the NHS – Health data lake	-	35	65	100	-

		Agreements with Autonomous Communities within the framework of the Digital Health Strategy of the NHS – Digital transformation of healthcare in primary and community care	-	70	160	230	-
	Actions in the field of AI	Programme of missions in AI, health sector	10	-	-	10	4.28
		Integration of AI in value chain, health sector	15	-	-	15	6.42
		Multidisciplinary centre for application of AI for the development of health	-	40	-	40	60
Actions associated with cross-cutting line 1: Development and strengthening of capacities of NHS for clinical research. ISCIII platform for clinical research (SCREN) (*the amount of this measure is included in the total amount allocated to platforms to support R&D and the transfer of knowledge)		ISCIII-autonomous region agreements. Strengthening clinical research capacities of NHS (infrastructures, digitalisation, clinical trial units)	-	-	-	ERDF (to be scheduled)	-
		ISCIII platform for clinical research (SCREN) (*the amount of this measure is included in the total amount allocated to platforms to support R&D and the transfer of knowledge)	-	-	-	-	-

Scope of action	Action	Measure	Public contribution in 2021	Public contribution in 2022	Public contribution in 2023	Public contribution (million euros)	Private Investment (million euros)
Actions associated with Cross-cutting Line 2: Innovation and strengthening industry		MINCOTUR Call for proposals for support for industrial innovation and sustainability projects in processes and products in the pharmaceutical sector and for health products	-	32.5 grant 25 loan	17.5 grant 25 loan	100 (50 grant + 50 loan	150
		Direct co-investment in innovative companies in the field of biohealth to strengthen their technologic and industrial capacities through the company Innvierte	30	-	-	30	40
		Fund to support productive industrial Investment*	-	30 (loan)	30 (loan)	60 (loan)	75
		Line of support for R&D+i projects in the field of connected industry-active financing*	-	2.5 grant 5 loan	1.5 grant 4 loan	13 (4 grant + 9 loan)	20
		Line of support for innovation and sustainability plans in the field of manufacturing industry*	-	2.95 grant 4 loan	2.95 grant 4 loan	13.9 (5.9 grant + 8 loan)	21

Scope of action	Action	Measure	Public contribution in 2021	Public contribution in 2022	Public contribution in 2023	Public contribution (million euros)	Private Investment (million euros)
Actions associated with Cross-cutting Line 3: Collaboration and coordination for transfer of knowledge		Portfolio of health innovation projects (*the amount of this measure is included in the total amount allocated to platforms to support R&D and the transfer of knowledge)	-	-	-	-	-
		System to monitor projects in pre-clinical phases (*the amount of this measure is included in the total amount allocated to platforms to support R&D and the transfer of knowledge)	-	-	-	-	-
		Funds for transfer of specialised technology in the field of biohealth, set up through the company Innvierte	40	-	-	40	35
Actions associated with Cross-cutting Line 4: Territorial cohesion		Supplementary R&D+i plans in biotechnology applied to health (co-investment with Autonomous Communities)	32	-	-	32	-

Scope of action	Action	Measure	Public contribution in 2021	Public contribution in 2022	Public contribution in 2023	Public contribution (million euros)	Private Investment (million euros)
Actions associated with Cross-cutting Line 5: Training		Training support for management of research in health (Carlos III Health Institute)	0.4535	0.4535	-	0.907	-
		Training centre in "Cutting-edge Health"	-	-	-	-	2
		Acquisition of digital skills	-	1	2	3	-
		Support programme to attract talent	-	-	3.6	3.6	-
TOTAL 1.469			**982,442 393,942 MCIN (349,025 C17PRR + 44,917 GSB) 401,600 MINECO and M. HEALTH (230 C11+ 25 C16 + 100 C18 + 6.6 C19) 186.9m (109.9 C12 MINCOTUR + 77 GSB)**				**486,82**

España transforma

GOBIERNO DE ESPAÑA

Plan de Recuperación Transformación y Resiliencia